Wang, Rutao
Lunardi, Mattia
Hara, Hironori
Gao, Chao
Ono, Masafumi
Davierwala, Piroze M.
Holmes, David R.
Mohr, Friedrich W.
Curzen, Nick
Burzotta, Francesco
van Geuns, Robert-Jan
Kappetein, Arie Pieter
Head, Stuart J.
Thuijs, Daniel J. F. M.
Tao, Ling
Garg, Scot
Onuma, Yoshinobu
Wijns, William
Serruys, Patrick W. http://orcid.org/0000-0002-9636-1104
Clinical trials referenced in this document:
Documents that mention this clinical trial
Impact of repeat revascularization within 5 years on 10-year mortality after percutaneous or surgical revascularization
https://doi.org/10.1007/s00392-023-02211-6
Impact of established cardiovascular disease on 10-year death after coronary revascularization for complex coronary artery disease
https://doi.org/10.1007/s00392-021-01922-y
Effect of Patient-Reported Preprocedural Physical and Mental Health on 10-Year Mortality After Percutaneous or Surgical Coronary Revascularization
https://doi.org/10.1161/circulationaha.121.057021
Ten-Year All-Cause Death According to Completeness of Revascularization in Patients With Three-Vessel Disease or Left Main Coronary Artery Disease: Insights From the SYNTAX Extended Survival Study
https://doi.org/10.1161/circulationaha.120.046289
Mortality after multivessel revascularisation involving the proximal left anterior descending artery
https://doi.org/10.1136/heartjnl-2022-320934
Documents that mention this clinical trial
Impact of repeat revascularization within 5 years on 10-year mortality after percutaneous or surgical revascularization
https://doi.org/10.1007/s00392-023-02211-6
The impact of a second arterial graft on 5-year outcomes after coronary artery bypass grafting in the Synergy Between Percutaneous Coronary Intervention With TAXUS and Cardiac Surgery Trial and Registry
https://doi.org/10.1016/j.jtcvs.2015.05.010
Transcatheter therapies for mitral regurgitation
https://doi.org/10.1016/j.jtcvs.2013.12.002
Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial
https://doi.org/10.1016/s0140-6736(13)60141-5
Anatomical and clinical characteristics to guide decision making between coronary artery bypass surgery and percutaneous coronary intervention for individual patients: development and validation of SYNTAX score II
https://doi.org/10.1016/s0140-6736(13)60108-7
Impact of established cardiovascular disease on 10-year death after coronary revascularization for complex coronary artery disease
https://doi.org/10.1007/s00392-021-01922-y
Complex coronary anatomy in coronary artery bypass graft surgery: Impact of complex coronary anatomy in modern bypass surgery? Lessons learned from the SYNTAX trial after two years
https://doi.org/10.1016/j.jtcvs.2010.07.094
Percutaneous Coronary Intervention Versus Coronary Artery Bypass Grafting in Patients With Left Main Disease With and Without Diabetes: Findings From a Pooled Analysis of 4 Randomized Clinical Trials
https://doi.org/10.1161/circulationaha.123.065571
Coronary bypass surgery versus stenting in multivessel disease involving the proximal left anterior descending coronary artery
https://doi.org/10.1136/heartjnl-2016-309720
Effect of Patient-Reported Preprocedural Physical and Mental Health on 10-Year Mortality After Percutaneous or Surgical Coronary Revascularization
https://doi.org/10.1161/circulationaha.121.057021
Ten-Year All-Cause Death According to Completeness of Revascularization in Patients With Three-Vessel Disease or Left Main Coronary Artery Disease: Insights From the SYNTAX Extended Survival Study
https://doi.org/10.1161/circulationaha.120.046289
Mortality after multivessel revascularisation involving the proximal left anterior descending artery
https://doi.org/10.1136/heartjnl-2022-320934
Funding for this research was provided by:
German Foundation of Heart Research
Science Foundation Ireland (Research Professorship Grant 15/RP/2765)
National University Ireland, Galway
Article History
Received: 28 January 2023
Accepted: 17 April 2023
First Online: 8 May 2023
Declarations
:
: Dr. Burzotta reports speaker’s fees from Abiomed, Abbott, Terumo and Medtronic. Dr. Hara reports a grant for studying overseas from Japanese Circulation Society, a grant-in-Aid for JSPS Fellows, a grant-in-aid from Japan Foundation for Applied Enzymology, and a grant from Fukuda Foundation for Medical Technology. Dr. Davierwala reports speaker’s fees from Medtronic. Dr. Davierwala holds the Angelo & Lorenza De Gasperis Chair in Cardiovascular Surgery Research, an endowed joint Hospital-University Chair among University Health Network (UHN), the University of Toronto (UofT), and UHN Foundation. Dr. Head reports working as a full-time employee of Medtronic outside the scope of this work. Dr. Kappetein reports working as an employee of Medtronic, outside the submitted work. Dr. Serruys reports personal fees from Biosensors, Micel Technologies, Sinomedical Sciences Technology, Philips/Volcano, Xeltis, and HeartFlow, outside the submitted work. Dr. Wijns reports working as Co-founder of Argonauts, an innovation facilitator. All other authors have no disclosures.